ENTITY
Neuren Pharmaceuticals

Neuren Pharmaceuticals (NEU AU)

41
Analysis
Health CareAustralia
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company. The Company researches neurological and metabolic disorders.
more
14 Nov 2024 22:09

Neuren Pharmaceuticals (NEU AU): Substantial Buyback Plan Announced; Daybue Sales Accelerate in US

​Neuren announces A$50M share buy-back program following the company's recent entitlement of one-off income from the sale of partner’s Priority...

Logo
153 Views
Share
05 Sep 2024 23:44

Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather

​Neuren shares dip due to disappointing U.S. performance of Daybue. Muted US performance of Daybue in 1H24 seems to be short-lived and the drug is...

Logo
373 Views
Share
20 Dec 2023 09:30

Neuren Pharmaceuticals (NEU AU): Positive Trial Result- A Step Ahead for Potential Second Drug

​Neuren announced positive phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, a genetic disorder. NNZ-2591 has the potential to become...

Logo
409 Views
Share
21 Dec 2023 09:30

2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...

Logo
604 Views
Share
20 Oct 2024 07:30

APAC Healthcare Weekly (Oct 20)- Eisai, Daiichi Sankyo, Junshi Bioscience, Akeso, Celltrion, Neuren

This insight collates key news in APAC healthcare last week. With the earnings season beginning to unfold along with major pharma and healthcare...

Logo
355 Views
Share
x